Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Viking Therapeutics Inc. | VK5211 | Hip fracture, Muscle Wasting | Phase 2 | Enrollment Conclusion | oral | Orthopedic |
| Viking Therapeutics Inc. | VK2735 - (VENTURE) | Obesity | Phase 2a | Data Released | Subcutaneous | Endocrinology |
| Viking Therapeutics Inc. | VK0612 | Type 2 Diabetes | Phase 2a | Enrollment Conclusion | oral | Endocrinology |
| Vincerx Pharma Inc. | OQY-3258 (ESG401) | Unresectable recurrent or metastatic triple-negative breast cancer | Phase 3 | Ongoing | oral | Oncology |
| Vincerx Pharma Inc. | OQY-3258 (ESG401) | Advanced or metastatic HR+/​HER2- breast cancer | Phase 3 | Ongoing | oral | Oncology |
| Vir Biotechnology Inc. | Tobevibart and Elebsiran - (ECLIPSE-1) | Chronic hepatitis delta infection | Phase 3 | Ongoing | Subcutaneous | Antiviral |
| Vir Biotechnology Inc. | Ensovibep (VIR-7831 / GSK4182136) - (ACTIV-3) | Mild to moderate COVID-19 | Phase 3 | Withdrawn | Intravenous | COVID-19 |
| Vir Biotechnology Inc. | VIR-2218 and VIR-3434 - (SOLSTICE) | Chronic Hepatitis D Virus Infection | Phase 2 | Ongoing | Subcutaneous | Antiviral |
